Discontinuing Coverage on Dalrada (DFCO).
We Are Temporarily Discontinuing Coverage on Dalrada Financial.
Great little company and we're up 400%. But with the market...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
There’s Simply No Loyalty Anymore.
TODAY'S LETTER
Frontier Bio (FBIO) $3.90. We Have Another Double! American BriVision (ABVC) $4.00. Wait, What? Yet...
Adding American BriVision (ABVC) $2.00 to Watch List.
New client and an incubator, studying now. Thinly, thinly traded. We like what we've read so far about their vitreous substitute (eyeball...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in FDA Trials!
Great headline, right?
The actual headline was: Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...